TG Therapeutics
TGTX
Market cap $3.61B

23.31 USD

-0.63

2.63%

At close Oct 18, 4:00 PM EDT

After hours

23.31

+0.00

0.00%

1 day

-2.63%

5 days

5.62%

1 month

-7.68%

3 months

9.80%

6 months

66.62%

Year to date

36.80%

1 year

240.79%

5 years

326.92%

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,740 funds

0

Analysts bullish %

of 4 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

59% more first-time investments, than exits

New positions opened: 51 | Existing positions closed: 32

39% more call options, than puts

Call options by funds: $49M | Put options by funds: $35.3M

38% more repeat investments, than reductions

Existing positions increased: 91 | Existing positions reduced: 66

20% more capital invested

Capital invested by funds: $1.39B [Q1] → $1.67B (+$281M) [Q2]

20% more funds holding in top 10

Funds holding in top 10: 5 [Q1] → 6 (+1) [Q2]

8% more funds holding

Funds holding: 234 [Q1] → 253 (+19) [Q2]

1.72% more ownership

Funds ownership: 58.66% [Q1] → 60.38% (+1.72%) [Q2]

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$20

14%

downside

Avg. target

$38

63%

upside

High target

$49

110%

upside

4 analyst ratings

3 positive

75%

1 neutral

25%

0 negative

0%

HC Wainwright & Co. Edward White 37% 1-year accuracy 22 / 59 met price target	110%upside $49	Buy Reiterated	18 Sept 2024
B. Riley Securities Mayank Mamtani 48% 1-year accuracy 11 / 23 met price target	46%upside $34	Buy Maintained	7 Aug 2024
Goldman Sachs Corinne Jenkins 100% 1-year accuracy 3 / 3 met price target	14%downside $20	Neutral Maintained	7 Aug 2024
HC Wainwright & Co. Edward White 37% 1-year accuracy 22 / 59 met price target	110%upside $49	Buy Reiterated	6 Aug 2024

See Analyst Rankings

Financial journalist opinion

Investors Business Daily

Hunting For Magnificent Growth Next Year? Check Out These 7 Stocks.

None of our picks is Nvidia or Apple or Tesla. Investors may wish to widen the aperture to find the best stocks for outsize earnings growth.

Hunting For Magnificent Growth Next Year? Check Out These 7 Stocks.

TG Therapeutics: A Look At New Briumvi Data And Ocrevus Zunovo Approval

Shares of TG Therapeutics made new 52-week highs this week, helped in part by new Briumvi data presentations at ECTRIMS and despite Roche receiving FDA approval for Ocrevus Zunovo. Ocrevus Zunovo's convenience profile does not look threatening and Roche believes it represents an incremental growth opportunity, primarily in treatment centers where IV infusions are not possible. Convenience should also be the third consideration for patients, after efficacy and safety, and Briumvi's position on both still looks strong.

TG Therapeutics: A Look At New Briumvi Data And Ocrevus Zunovo Approval

New BRIUMVI® (ublituximab-xiiy) Data from the ENHANCE Phase 3b Study Show Rapid 30-Minute Infusions are Well Tolerated in Patients with Relapsing Forms of Multiple Sclerosis

Infusion related reactions in patients receiving 30-minute BRIUMVI infusions were all mild (Grade 1) and resolved completely Data also demonstrate patients switching from prior anti-CD20 treatment can successfully eliminate initial BRIUMVI infusion NEW YORK, Sept. 18, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today presented updated data from the ENHANCE Phase 3b trial evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting.

New BRIUMVI® (ublituximab-xiiy) Data from the ENHANCE Phase 3b Study Show Rapid 30-Minute Infusions are Well Tolerated in Patients with Relapsing Forms of Multiple Sclerosis

New Data for BRIUMVI® (ublituximab-xiiy) Demonstrate that 92% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 5 Years of Treatment

During year 5 of treatment with BRIUMVI the annualized relapse rate was 0.020, equivalent to one relapse occurring every 50 years of patient treatment

New Data for BRIUMVI® (ublituximab-xiiy) Demonstrate that 92% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 5 Years of Treatment

Schaeffers Research

These 12 Stocks are Ripe for a Short Squeeze

Subscribers to Chart of the Week received this commentary on Sunday, September 8.

These 12 Stocks are Ripe for a Short Squeeze

Investors Business Daily

Four Biotech Stocks Rally Toward Buy Points As Funds Load Up

Biotech stocks have been rallying as funds load up. Five stocks have been outperforming the vast majority in the IBD database.

Four Biotech Stocks Rally Toward Buy Points As Funds Load Up

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI at the 2024 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting

NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming data presentations, highlighting data from both the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting, being held September 18 – 20, 2024, in Copenhagen, Denmark. Abstracts are now available online and can be accessed on the ECTRIMS meeting website or at the following link: ECTRIMS 2024 Programme. Details of the presentations are outlined below.

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI at the 2024 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting

TG Therapeutics Delivers A Beat-And-Raise Q2 And A $100 Million Buyback

TG Therapeutics exceeded Q2 Street consensus estimates, with Briumvi net sales of $72.6 million and total revenues of $73.5 million. Positive cash flow achieved one quarter ahead of my expectations, and full-year guidance range raised by $15 million at the mid-point of the range. TG secured a new $250 million credit facility to retire the old one, and it will use $100 million to buy back shares.

TG Therapeutics Delivers A Beat-And-Raise Q2 And A $100 Million Buyback

TG Therapeutics, Inc. (TGTX) Q2 2024 Earnings Call Transcript

TG Therapeutics, Inc. (NASDAQ:TGTX ) Q2 2024 Earnings Conference Call August 6, 2024 8:30 AM ET Company Participants Michael Weiss - Chairman, Chief Executive Officer Adam Waldman - Chief Commercialization Officer Sean Power - Chief Financial Officer Jenna Bosco - Senior Vice President of Corporate Communications Conference Call Participants Roger Song - Jefferies Matt Kaplan - Ladenburg Thalmann Michael DiFiore - Evercore ISI Eric Joseph - JP Morgan Mayank Mamtani - B. Riley Securities Prakhar Agrawal - Cantor Fitzgerald Ed White - H.C.

TG Therapeutics, Inc. (TGTX) Q2 2024 Earnings Call Transcript

Schaeffers Research

2 Biotech Stocks Making Moves Today

Last month, we took a look at three biotech stocks following a historically bullish month for biotech exchange-traded fund (ETF) SPDR S&P Biotech ETF (XBI).

2 Biotech Stocks Making Moves Today

See News Rankings

Charts implemented using Lightweight Charts™